KKR to Acquire Pan-European Live Entertainment Group Superstruct from Providence Equity Partners
21.6.2024 17:45:00 EEST | Business Wire | Press release
KKR, a leading global investment firm, today announces the acquisition of Superstruct Entertainment (“Superstruct” or the “Company”), from Providence Equity Partners (“Providence”), a premier private equity firm specializing in growth-oriented investments in media, communications, education and technology. Financial terms of the transaction were not disclosed.
Superstruct is an entrepreneurial and leading European live entertainment group, owning and operating over 80 music festivals across 10 countries in Europe and Australia. Since its establishment in 2017 by Providence, Superstruct has grown organically and through acquisitions into one of the world’s premier live entertainment groups. Today, the company has a well-diversified portfolio across music genres and geographies. The portfolio includes some of Europe’s most popular and high-quality festivals, such as Wacken Open Air, Defqon.1, Parookaville, Sziget, Tinderbox, Boardmasters and Sónar.
Demand for live entertainment has grown significantly over the past decade and is expected to continue to expand, as consumer spending continues to shift from goods towards experience. KKR will support Superstruct in its next phase of development as one of the key players in a highly fragmented sector that continues to grow, expand and professionalise, whilst preserving the creative and cultural DNA of the Company.
As part of the transaction, Providence has an option to invest €250 million into Superstruct.
Philipp Freise, Partner and Co-Head of European Private Equity and Franziska Kayser, Partner at KKR, said: “We are delighted to partner with Roderik Schlösser, James Barton and the team at Superstruct who have established themselves as a leader in delivering unparalleled live music experiences globally. With a robust foundation as a top-tier live entertainment platform, we see significant growth opportunities ahead for Superstruct. Drawing on our strong partnership approach and experience in the digital entertainment and ticketing space, such as BMG, ProSiebenSat1, GetYourGuide, and Trainline, as well as KKR’s global resources and extensive network, we will support the company and its entrepreneurial team to bring their compelling portfolio of live event formats to a wider audience and drive further growth.”
Andrew Tisdale, Senior Managing Director and Daniel Zwicky, Director at Providence Equity Partners, said: “We are incredibly proud of the rapid growth and success Superstruct has achieved since its inception. With Providence’s backing, Superstruct has become a truly exceptional live entertainment company. In particular, we believe the Company’s resilience and emergence from the global pandemic as a stronger business is testament to the entrepreneurial spirit of Roderik Schlösser, James Barton and the impressive management team. We are confident that with KKR’s support, Superstruct will continue to thrive.”
Roderik Schlösser, CEO and James Barton, Chairman of Superstruct Entertainment said: “The founding vision for Superstruct was to create a natural home for successful entrepreneurs, creative visionaries, and business-minded professionals in live entertainment. We wanted to create a network of influence setting the standards for live experiences. Through our development, we are a leader in the professionalization of this industry, enabling our dedicated teams to excel in a collaborative and inspiring environment and create and deliver best-in-class events for millions of fans. We are proud to have secured the backing of KKR, whose expertise and network will strengthen our ability to scale and innovate in the vibrant experiential economy. We would like to thank Andrew Tisdale, Daniel Zwicky and the team at Providence for their outstanding support. Their belief in Superstruct has been fundamental to our success.”
KKR has an extensive European track record and operational experience in developing regional platform businesses in the consumer and TMT sectors, including investments in Trainline, GetYourGuide, Mediawan/Leonine, ProSiebenSat1, GfK and Axel Springer. With its investment in Superstruct, KKR will draw from direct experience working with independent music businesses, including global music company BMG, helping the business deliver its vision of supporting songwriters and treasuring their artistry. KKR is making the investment in Superstruct through its European Fund VI, an $8 billion fund that invests in the growth of leading businesses by providing access to KKR’s extensive network and business building resources. Recent investments from European Fund VI include FGS Global, OHB and Nexeye. Across all investments, KKR is differentiated by its strong partnership approach in working closely with portfolio company management teams through their transformation and growth.
Goldman Sachs is acting as financial advisor and Kirkland & Ellis as legal advisor to KKR. Providence is being advised by HSBC and LionTree as joint financial advisors, and White & Case as legal advisor.
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKRs website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.
About Providence Equity Partners
Providence Equity Partners is a specialist private equity investment firm focused on growth-oriented media, communications, education and technology companies across North America and Europe. Providence combines its partnership approach to investing with deep industry expertise to help management teams build exceptional businesses and generate attractive returns. Since its founding in 1989, Providence has invested over $36 billion across more than 175 private equity portfolio companies. With its headquarters in Providence, RI, the firm also has offices in New York, London, Boston and Atlanta. For more information, please visit www.provequity.com.
About Superstruct Entertainment
Founded in 2017 by James Barton and Roderik Schlosser, Superstruct is a European leader in live entertainment. Its well-diversified portfolio includes some of Europe’s most popular festivals and live event formats, among them Flow, Arenal Sound, Zwarte Cross, elrow, Victorious, Resurrection Fest and Lost Village, alongside established capabilities in brand partnerships, merchandise, staging and travel solutions. To connect with Superstruct, visit www.superstruct.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240621755499/en/
Contacts
KKR:
Alastair Elwen / Mei Futonaka
FGS Global
+44 20 7251 3801
KKR-LON@fgsglobal.com
Providence Equity Partners:
Charlie Chichester / Rory King
FGS Global
+44 20 7251 3801
ProvidenceEquity@fgsglobal.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom